Viking Therapeutics has announced a Phase 3 program for daily tablets of VK2735, its investigational dual GIP/GLP-1 receptor agonist. The SUNRISE trials will test weight change over 68 weeks in two separate populations: adults without type 2 diabetes and adults with it. This is a development milestone, not a report of new weight-loss results or an approval.
The useful question is what longer follow-up can establish. A daily tablet may appeal to people who dislike injections, but convenience alone does not show how much weight people will lose, how many will stay on treatment or how tolerable it will be over time. SUNRISE is designed to collect evidence on those questions.
Two trials, with diabetes status kept separate
In its October 14 sponsor announcement, Viking described SUNRISE-1 and SUNRISE-2 as randomized, double-blind, placebo-controlled studies, each targeting 560 participants. Random assignment helps make the treatment groups comparable, while masking participants and investigators reduces the influence of knowing which treatment someone receives.
The SUNRISE-1 registry record specifies adults without type 2 diabetes who have a BMI of at least 30, or at least 27 with a weight-related condition. The SUNRISE-2 record specifies adults with type 2 diabetes and a BMI of at least 27, with additional glucose-control and treatment eligibility criteria. These are study populations, not a self-assessment tool for deciding whether to use a medicine.
Both studies compare three once-daily oral target doses—27.5 mg, 35 mg and 55 mg—with placebo. The registries describe gradual dose escalation before participants reach their assigned target. These amounts describe experimental regimens under trial supervision; they are not prescribing guidance or equivalents for another product.
The registered primary outcome is percentage change in body weight from baseline to week 68, comparing each dose separately with placebo. The two populations should remain separate when results arrive. Combining their averages would obscure which result applies to which group.
A launch announcement is not a results timetable
The registry versions posted on October 9 still listed both trials as “not yet recruiting” when checked on October 15. Their estimated start dates were October 15 for SUNRISE-1 and October 16 for SUNRISE-2. Viking’s October 14 announcement is newer than those posted records. The sources therefore describe different dated snapshots; they do not establish that recruitment is currently open at a particular clinic.
The records estimate primary completion in July 2028 and October 2028, respectively. Primary completion concerns collection of the primary-outcome data, not publication, regulatory submission or approval. Those dates can change, and a 68-week treatment period does not mean results will appear 68 weeks after the press release: participants need to enter and complete the study.
What the next results need to show
Neither registry contains posted results. The announcement refers back to the earlier 13-week VENTURE-Oral study, but those short-term findings are not a forecast of SUNRISE’s 68-week outcome. This article reviews the new announcement and registered designs, not the earlier trial’s full paper or supplementary analyses.
When results are released, the weight-loss percentage will need an explanation of who it represents. Does the analysis estimate outcomes regardless of stopping assigned treatment, or under assumptions about remaining on it? The inspected registry summaries identify the primary endpoint but do not provide the complete statistical analysis plan needed to resolve that question. Our guide to trial estimands explains why those approaches can yield different answers.
Discontinuations and missing measurements will matter alongside the average weight change. A favorable result among people able to remain on treatment cannot, by itself, describe the experience of everyone who started. Reporting the reasons for leaving, adverse events by dose and follow-up after discontinuation will make the findings more useful. See our guide to discontinuation and tolerability for that distinction.
These are placebo comparisons, not head-to-head comparisons with another weight-loss drug. VK2735 shares the GIP/GLP-1 receptor targets described in our tirzepatide profile, but shared targets do not establish equal benefit, safety or interchangeable doses. Nor can an apparent difference between unrelated trials settle which medicine works better.
Daily treatment and maintenance are different questions
SUNRISE evaluates daily oral treatment for weight management. Viking also has a separate oral-maintenance study and the VANQUISH program for weekly injections. Evidence about one route or treatment phase cannot automatically answer questions about another.
The October 14 release includes a correction to Viking’s October 6 maintenance announcement: its reference to weekly oral doses was incorrect. The sponsor now describes daily oral maintenance doses alongside less-frequent injection options and placebo. Readers who saw the earlier weekly-tablet wording should use this correction; SUNRISE does not test a weekly tablet.
For now, the practical development is a larger, longer test of an investigational oral medicine. A tablet’s real-world usefulness will depend on efficacy, tolerability and the eventual instructions and access conditions, if it is approved. Our oral-versus-injectable guide explains the broader practical questions without assuming every tablet has the same requirements.



